Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Go back to Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 52.42 -0.39 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.81 | 52 Week High | $45.58 | |||
| Open | $52.59 | 52 Week Low | $37.82 | |||
| Day High | $52.69 | P/E | N/A | |||
| Day Low | $51.51 | EPS | $0.00 | |||
| Volume | 4,011,093 | |||||
| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 52.42 -0.39 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $52.81 | 52 Week High | $45.58 | |||
| Open | $52.59 | 52 Week Low | $37.82 | |||
| Day High | $52.69 | P/E | N/A | |||
| Day Low | $51.51 | EPS | $0.00 | |||
| Volume | 4,011,093 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.08 -0.29 (1.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.37 | 52 Week High | $37.39 | |||
| Open | $24.43 | 52 Week Low | $28.25 | |||
| Day High | $24.46 | P/E | 14.59 | |||
| Day Low | $23.78 | EPS | $1.65 | |||
| Volume | 60,027,317 | |||||

